Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kinoxis Therapeutics Pty Ltd. is currently managing a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently awaiting a response. This 1 action is being handled by 1 distinct examiner, which indicates that the company's immediate prosecution workload is concentrated rather than distributed across multiple officials. Such a focused docket allows for a highly specific legal strategy tailored to the requirements of the point of contact at the patent office.
The busiest examiner for this portfolio is LEE, WILLIAM Y, who is responsible for the 1 busiest examiner pending action. Because this examiner is the only 1 identified in the current data, their individual review style will be the primary factor in the portfolio's near-term progress. Furthermore, the prosecution is limited to 1 distinct art unit. This suggests that the company's current intellectual property efforts are confined to a specific technical niche within the biotechnology field, requiring specialized expertise from both the examiner and the applicant's counsel to navigate the examination process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17932914 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | LEE, WILLIAM Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17932914 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17932914 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | LEE, WILLIAM Y | 1623 | §102§112 | Non-Final OA | — | Pending | Sep 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKinoxis Therapeutics Pty Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William Y Lee has the most, with 1 of Kinoxis Therapeutics Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
